A complex research article appeared in Nature Genetics on 15 September 2026, titled ‘Type 1 interferon perturbates clonal competition by reshaping human blood development’.
It is an important article for the MPN community as it examines how interferon changes blood stem cells in MPNs.
————————————————————————————
Due to the complexity of the article, the MPN AA used AI for a patient-friendly summary – see below.
However as AI can be inaccurate, if you wish to clarify something, please check the actual article.
The main message
This research helps explain how interferon-alpha (pegylated interferon) can do more than control blood counts in MPN patients. It can actually change behaviour of the abnormal blood stem cells responsible for the disease, potentially reducing their numbers over time.
This is important because it provides a better understanding of why interferon can produce a molecular response, rather than simply treating the symptoms of an MPN.
Why did researchers undertake this study?
MPNs such as polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis (MF) are driven by abnormal mutations in blood stem cells. MPN mutations include JAK2, CALR and MPL which cause the bone marrow to produce blood cells in abnormal quantities.
People with MPNs also tend to have increased inflammation, which can encourage abnormal blood stem cells to survive and multiply.
Interferon-alpha can control blood counts, and can reduce the proportion of blood stem cells carrying disease-causing mutations (ie this is sometimes known as reducing the allele burden or having a molecular response). Researchers wanted to understand exactly how this happens.
What did the researchers do?
They examined blood stem cells and their developing offspring in patients with MPNs before and after treatment with pegylated interferon-alpha. Using sophisticated technology that examined individual cells, they could distinguish between: mutated cells – carrying the genetic changes responsible for the MPN; and normal cells – not carrying those MPN-driving mutations.
This allowed them to see how interferon affected the two populations differently.
What did they discover?
Interferon appears to change blood stem cells in three important ways.
A) Interferon encourages blood stem cells to develop along different pathways.
Interferon activates stem cells and encourages them to produce two different groups of developing blood cells:
- Lymphoid cells: These are important components of the immune system. Their increased production helps counterbalance the abnormal overproduction of myeloid cells seen in MPNs.
- Myeloid cells: Interferon also stimulates a more inflammatory pathway, encouraging the production of cells such as neutrophils.
The researchers found that this change helps restore a healthier balance in blood cell development.
B) Interferon changes the competitive advantage of abnormal stem cells
This is perhaps the most interesting finding. Normally, MPN-mutated stem cells have an advantage over normal stem cells, allowing them to multiply and dominate the bone marrow. Interferon changes this competition. It makes the abnormal stem cells more vulnerable to certain effects of treatment, potentially reducing their ability to maintain their dominance.
However, the researchers also discovered that JAK2 and CALR-mutated stem cells have some resistance to being pushed into the inflammatory myeloid pathway. This helps explain why some abnormal cells survive treatment even when patients experience a good clinical response.
C) Interferon influences inflammation
Interferon also suppressed certain inflammatory gene programmes associated with ageing and chronic inflammation. This is significant because inflammation is thought to contribute to the development and progression of MPNs.
Why is this important for patients?
The research provides further evidence that interferon is fundamentally different from treatments that simply reduce blood counts. Its potential benefits include:
- Reducing the proportion of blood stem cells carrying disease-causing mutations.
- Changing the way abnormal stem cells develop.
- Helping restore a more normal balance between blood cell types.
- Reducing certain inflammatory processes.
- Potentially modifying the underlying biology of the MPN rather than just controlling its symptoms.
These effects help explain why patients can experience improvements in their MPN even when their mutation levels have not fallen substantially.
What does this research mean for the future?
The findings could help researchers develop more effective treatments that specifically target abnormal blood stem cells. They may also help explain why some patients respond better to interferon than others. One possibility is that scientists could develop treatments that reproduce the beneficial effects of interferon on abnormal stem cells, potentially with fewer side effects. The researchers are also now looking at investigating whether natural interferon-alpha contributes to some autoimmune conditions through its aberrant triggering of this highly inflammatory infection-fighting response.
What should patients understand about the limitations?
While this is important research, there are some qualifications:
- The study was relatively small, with detailed cellular analysis of samples from 13 patients.
- Much of the research focused on CALR-mutated ET, so the findings cannot automatically be applied equally to all forms of PV, ET and MF.
- Although JAK2 mutations were also investigated, more research is needed to establish how the findings translate into clinical outcomes for JAK2-positive PV.
- The study does not establish that interferon eliminates all abnormal stem cells or cures MPNs.
- It does not establish that interferon has the same effects on other mutations, such as TET2 and DNMT3A.
Take away message
Interferon does more than control blood counts. This research provides important evidence that interferon can change the behaviour of blood stem cells, influence which cells survive and multiply, and reshape the development of blood cells. In doing so, it may help reduce the dominance of abnormal MPN stem cells and modify the underlying disease process.
This research gives us a better understanding of the biological mechanisms behind interferon’s disease-modifying potential. It also reinforces why molecular responses — reductions in the allele burden (percentage of blood cells carrying an MPN mutation) — are an important area of research, rather than looking at blood counts alone.
A question for future research is whether these same mechanisms can be harnessed to reduce other abnormal clones, including those associated with CHIP. This study does not answer that question, but it provides a foundation for investigating it.
The full article, ‘Type 1 interferon perturbates clonal competition by reshaping human blood development’, is freely available.
A media release from Weill Cornell Medicine about the article is available.
NOTE FROM THE MPN AA
As mentioned, AI was used for the above patient-friendly interpretation of the research.
The article is not a clinical treatment recommendation.
Clinicians take a range of factors into account when considering and prescribing interferon for their patients.
We also remind readers of a recent article about interferon and autoimmunity.
